Arbutus Biopharma | Investor Presentation Deck | 28 slides

Arbutus Biopharma · 2023-05
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

28
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide uses a two-column layout to present distinct therapeutic focus areas.present_solution
Open slide detailBeat · Solution & ApproachLoop · Logic Chain
04
The slide uses a column-based layout with icons and supporting text to summarize company strengths.summarize
Open slide detailBeat · Solution & ApproachLoop · Logic Chain
05
The slide uses a Gantt-style chart to show the status of various drug candidates (AB-729, AB-161, AB-101, AB-343) in HBV and COVID-19 programs.plan_implementation
Open slide detailBeat · Solution & ApproachLoop · Logic Chain
06
The slide uses a four-column layout to structure the disease overview.establish_context
Open slide detailBeat · Situation & ContextLoop · Logic Chain
07
Uses a nested circle diagram to represent the patient funnel (Total -> Diagnosed -> Treated).frame_problem
Open slide detailBeat · Problem & ComplicationLoop · Logic Chain
08
The slide uses a process-oriented flow diagram to explain the mechanism of action for a combination therapy.present_solution
Open slide detailBeat · Solution & ApproachLoop · Logic Chain
09
The slide highlights the mechanism of action and key clinical/preclinical benefits of the drug candidate.present_solution
Open slide detailBeat · Solution & ApproachLoop · Logic Chain
10
The slide outlines the study structure for a clinical trial, categorizing cohorts by dosage and patient status (HBV DNA +/-).present_framework
Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction
11
Data table includes standard error (SE) values for each mean. Footnote provides specific study parameters.analyze_data
Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction
12
The slide displays longitudinal data for cohorts E, F, I, J, G, and K, with specific callouts for individual patient outcomes.show_traction
Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction
13
The slide displays 8 individual patient charts tracking three biomarkers over 64 weeks. Two patients (53 and 58) show NA retreatment periods.show_traction
Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction
14
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.analyze_data
Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction
15
The slide uses a bulleted list to present clinical safety findings.summarize
Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction
16
The slide uses a four-column layout to present key findings from a clinical trial.summarize
Open slide detailBeat · Solution & ApproachLoop · Cost Of Inaction
17
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.plan_implementation
Open slide detailBeat · Solution & Approach
18
The slide outlines two distinct study arms involving AB-729, VTP-300, and Nivolumab, with a primary focus on safety and reactogenicity.plan_implementation
Open slide detailBeat · Solution & Approach
19
The slide details a licensing deal with Qilu Pharmaceutical, including financial terms and partner background.other
Open slide detailBeat · Solution & Approach
20
The slide uses a three-column layout to highlight key value propositions.present_solution
Open slide detailBeat · Solution & Approach
21
Includes a line chart for efficacy over time and two bar charts for pharmacokinetic concentrations in plasma vs liver.show_traction
Open slide detailBeat · Solution & Approach
22
Includes a disclaimer at the bottom regarding an FDA clinical hold.present_solution
Open slide detailBeat · Solution & Approach
23
The slide uses two distinct chart types (dose-response curve and bar chart) to show efficacy in two different biological assays.present_solution
Open slide detailBeat · Solution & Approach
24
establish_context
Open slide detailBeat · Solution & Approach
25
The slide uses a biological map of the coronavirus genome to justify targeting nsp5 and nsp12.present_solution
Open slide detailBeat · Solution & Approach
26
The slide highlights key therapeutic advantages of the candidate drug.present_solution
Open slide detailBeat · Solution & Approach
27
Includes a checkmark indicating completion of one milestone.plan_implementation
Open slide detailBeat · Solution & Approach
28
state_next_steps
Open slide detailBeat · Solution & Approach